Form 4: Iterum Therapeutics CCO Granted 200,000 Share Options Under Long-Term Incentive Plan

Iterum Therapeutics plc's Chief Commercial Officer, Christine Coyne, was granted 200,000 share options with an exercise price of $0.97, vesting over four years.

Summary

• Christine Coyne, Chief Commercial Officer of Iterum Therapeutics plc (ITRM), was granted 200,000 share options.
• The share options have an exercise price of $0.97 per share.
• The transaction date for this grant is July 1, 2025.
• The options will vest over a four-year period, with 25% vesting on the one-year anniversary of July 1, 2025 (July 1, 2026).
• The remaining 75% of the options will vest in equal monthly installments thereafter until July 1, 2029.
• The options are subject to Christine Coyne providing continuous service to Iterum Therapeutics plc on each relevant vesting date.
• The share options are set to expire on June 30, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of a significant number of share options to a key executive is generally positive, as it aligns the executive's financial interests with the long-term performance of the company and aids in retention.

Positives

• The grant of 200,000 share options to the Chief Commercial Officer signifies a substantial long-term incentive, aligning executive interests with shareholder value.
• The transaction was executed under a Rule 10b5-1(c) plan, demonstrating a pre-planned and compliant approach to insider equity transactions.

Risks

• The vesting of the share options is contingent upon the Chief Commercial Officer providing continuous service to Iterum Therapeutics plc, meaning unvested options could be forfeited if employment ceases.

Future Outlook

The vesting schedule for the share options extends until July 1, 2029, providing a long-term incentive for the Chief Commercial Officer. The options' expiration date of June 30, 2035, offers a significant window for potential exercise, aligning executive interests with the company's long-term performance.

Industry Context

The granting of long-term equity incentives, such as share options, is a standard practice in the biotechnology and pharmaceutical industries. This strategy is commonly employed to attract, retain, and motivate key executives, particularly those in critical commercial roles responsible for product development, market entry, and revenue generation.

Comparison to Industry Standards

• This document, a Form 4, reports a specific insider transaction and does not provide sufficient data for a detailed comparison of executive compensation packages or company performance against industry benchmarks or specific comparable companies/projects.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a key executive can be viewed positively as it aligns management's incentives with shareholder value creation and promotes long-term retention of critical talent.
• Employees: While not directly impacting all employees, the retention of key leadership can contribute to overall company stability and strategic direction.

Next Steps

• Continued service by Christine Coyne to ensure the vesting of the granted share options.
• Potential future exercise of the vested options by Christine Coyne, subject to market conditions and personal financial planning.

Key Dates

Keywords

Iterum Therapeutics, ITRM, Share Options, Stock Options, Executive Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting Schedule, Rule 10b5-1, Chief Commercial Officer